Logo

Developing the next evolution of oncolytic immunotherapy for patients with advanced cancers.

Our Science

Genetically engineered oncolytic immunotherapy with a multiple-pronged attack on cancer.

Learn More

May 16, 2022

CG Oncology Presents Additional Phase 2 Data with CG0070 in Combination with KEYTRUDA® (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

April 13, 2022

CG Oncology Presents Interim Phase 2 Data with CG0070 in Combination with KEYTRUDA® (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

 

 

December 20, 2021

CG Oncology Announces First Patient Dosed in Japan in Phase 3 Monotherapy Study of CG0070 in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

 

 

  • About
    • Overview
    • Management
    • Board of Directors
    • Contact
  • Pipeline
    • Overview
    • CG0070
    • CG0161
  • Technology
    • Overview
    • Publications
  • News
    • Press Releases
    • Conferences & Media
    • Media Contact
  • Careers
    • Overview
  • Contact
  • Home
  • About
    • Overview
    • Management
    • Board of Directors
    • Contact
  • Pipeline
    • Overview
    • CG0070
    • CG0161
  • Technology
    • Overview
    • Publications
  • News
    • Press Releases
    • Conferences & Media
    • Media Contact
  • Careers
    • Overview
  • Contact
  • LinkedIn
  • Twitter
  • Youtube
© 2022 CG Oncology, Inc. All rights reserved.
  • LinkedIn
  • Twitter
  • Youtube